Generex Biotechnology completes acquisition of Olaregen Therapeutix Inc

Source: CBNB

2019/02/12

Source: Company press release, 8 Jan 2019 , 8 Jan 2019 , Website: http://www.biospace.com Generex Biotechnology Corporation is pleased to announce that the
company has completed the acquisition of 51% of Olaregen Therapeutix Inc, a
US-based regenerative medicine company that is preparing to launch its
proprietary, patented, wound conforming gel matrix, Excellagen an FDA 510K
Cleared wound healing product cleared for the treatment of 17 types of
wounds including partial and full thickness wounds, pressure ulcers, venous
ulcers, diabetic ulcers, chronic vascular ulcers, tunnelled/undermined
wounds, surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser
surgery, podiatric, wound dehiscence), trauma wounds (abrasions,
lacerations, second-degree burns, and skin tears) and draining wounds. The
terms of the deal include the previously reported upfront payment of
$400,000, plus $11.6 M to be paid according to a milestone-based schedule.
Original Source: Generex Biotechnology Corporation, 2019. From website:
http://www.biospace.com. Released to ICIS 12 Feb 2019[This article was prepared by Chemical Business NewsBase (CBNB), a third party premium option available through ICIS news. For any queries about the content please contact: John Godfrey, godfreyj@elsevier.com, +44 (0) 1223 463167]